News & Events

New target for Cancer Immunotherapy

Disrupting N-glycan expression on tumor cells enhanced CAR T cell efficacy. Greco et al. treated mice with 2-deoxy-D-glucose (Focus Cat.# 10-2171), a glucose analog, disrupting N-glycan

READ MORE

PARP inhibitor approved by FDA

The FDA has approved the use of olaparib (Focus Cat.# 10-2154) as adjuvant treatment for patients with BRCA-mutated HER-2 negative high-risk early breast cancer that were

READ MORE

GPR35 and Neutrophil function

In a paper just out in Cell, Marco De Giovanni et al. at UCSF demonstrated that 5-hydroxyindoleacetic acid (5-HIAA), a platelet serotonin metabolite, acts as a

READ MORE

ABT-263 and Neurodegeneration

A team at Toronto’s Hospital for Sick Children demonstrated that pharmacological ablation of senescent cells using Navitoclax (ABT-263, Focus Cat#10-3141) caused a rapid increase in neural

READ MORE